INTERVIEWS

Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva Pharmaceutical Industries, Ltd, discusses the availability of AUSTEDO ® XR, a once-daily treatment for adults living with tardive dyskinesia and chorea associated with Huntington’s disease. Tardive dyskinesia and chorea associated with Huntington’s disease are debilitating chronic movement disorders. Tardive dyskinesia impacts 1 in 4 people who take certain mental health treatments and chorea occurs in approximately 90% of people living with HD. Dr. Hughes is here to discuss the availability of AUSTEDO ® XR, as well as recent data that was presented at the Schizophrenia International Research Society SIRS medical meeting in May 2023.

Eduardo Dunayevich, MD, Vice President, VMAT2 Franchise Leader, and Clinical Business Development Leader for Neurocrine Biosciences, Inc. discusses an involuntary movement disorder called tardive dyskinesia (TD) which is associated with prolonged use of certain mental health medicines (antipsychotics) that are used to treat depression, bipolar disorder, schizophrenia, and schizoaffective disorder. He talks about the symptoms of TD; the physical, emotional, and social impact of TD; and the importance of increasing awareness of TD, including the importance of regular screenings with a healthcare provider. For more information visit TalkAboutTD.com

Returning guest, Beth Battaglino, RN-C, CEO of HealthyWomen discusses the new survey results and outlines how those results call for encouraging better conversations between women of reproductive age and their healthcare professionals to ensure that women are being informed of their birth control options. In addition, she talks about the need to call for the development of even more innovative contraception options that meet the quickly changing needs of individuals of childbearing age.

Joe Todisco, CEO of CorMedix, a biopharmaceutical company focused on developing and commercializing therapeutic products that prevent infection and other life-threatening conditions, discusses the dangers of hospital and other related infections, as well as the urgency behind the global expansion of antimicrobial resistance, which is on the rise. He also talks about the company’s investigational catheter lock solution, DefenCath™, to reduce the risk of catheter-related bloodstream infections (CBRSIs) from central venous catheters (CVCs), which can dramatically increase hospital costs and length of stay. An NDA has been submitted to the FDA.

Dr. Patricia Hunt, PhD, Regents Professor in the School of Molecular Biosciences at Washington State University discusses her recent award, as well as her research in prenatal development and how it is impacted by aging, mistakes in meiosis, and environmental contaminants.

Dr. Peter Berglund, Chief Scientific Officer of HDT Bio, discusses the development of a next-generation RNA vaccine platform for infectious diseases and cancer. The RNA is self-replicating, meaning that it can produce a prolonged immunological effect at a much lower dose than the current RNA vaccines. The company has a COVID-19 vaccine candidate but is also focused on emerging pandemic threats and oncology indications, both in the U.S. and internationally.

Yael Shvetz, 54, shares her story of surviving a rare hemorrhagic stroke, or brain bleed, to inspire and educate other women like herself. She is part of the American Heart Association’s Go Red for Women 2023 Real Women Class of Survivors.

Allen Comer, Senior Director, Research at Stratatech Corporation, a Mallinckrodt company, discusses a recent advancement in burn care and why there should be a move past autografting for deep partial-thickness burns. He talks about a cutting-edge treatment now available. Patients should consult their health care practitioners to learn whether it is appropriate for them, and about safety information. Please click here for the important safety information and full prescribing information.

Dr. Christopher Flowers, M.D., Department of Lymphoma – Myeloma, Division of Cancer Medicine and chair of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center and POLARIX clinical trial investigator, shares his perspectives on the recent FDA approval of Polivy (polatuzumab vedotin-piiq) in combination with R-CHP as a first-line treatment for adults with certain types of diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer and the most common form of non-Hodgkin’s lymphoma in the U.S. For more information please visit www.lymphoma.org or lls.org.

Dr. Cynthia Silva, Vice President of Clinical Affairs at Outset Medical discusses a recent abstract that was presented at the National Kidney Foundation (NKF) Spring Clinical Meeting “Redefining dialysis care on the Hawaiian Islands: reducing health disparities and resource utilization” that found that Native Hawaiians and Pacific Islanders have the highest rates of diabetes, coronary artery disease and kidney disease of any racial group. Dr. Silva also discusses how implementation of Outset’s Tablo home hemodialysis (HHD) system expanded access to Native Hawaiians, demonstrated tolerance of the unique Hawaiian environment, and reduced cost of utilities resulting in a high treatment success rate. Additionally, she discusses what more needs to be done to increase access and reduce health disparities in kidney care and dialysis treatment, as well as the need for better education and awareness of kidney disease and prevention.